Eli Lilly's Foundayo Drug Shows Positive Weight-Loss Results in Phase 3
Eli Lilly's potential new weight-loss drug, Foundayo, demonstrated positive results in a Phase 3 trial for obesity and Type-2 diabetes, showing a non-inferior risk of major adverse cardiovascular events compared to alternatives.
Eli Lilly's potential new weight-loss drug Foundayo delivered positive results in a Phase 3 trial. Foundayo is being studied as a treatment for obesity and Type-2 diabetes and showed a non-inferior risk of major adverse cardiovascular events compared with the alternative treatment.